Ulsan University Hospital
87
13
19
36
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
2.3%
2 terminated/withdrawn out of 87 trials
94.7%
+8.1% vs industry average
18%
16 trials in Phase 3/4
14%
5 of 36 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (87)
Association Between 4D MRI Parameters and the Clinical Characteristics and Prognosis of Major Chronic Diseases
Role: lead
A Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of CANIUM Tab. in Acute Bronchitis Patients.
Role: collaborator
FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease
Role: collaborator
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
Role: collaborator
Long-term Prospective Study of Korean CADASIL Patients
Role: collaborator
Intravascular Ultrasound- and Angiography-Derived Fractional Flow Reserve-Guided Drug-Coated Balloon for Large Coronary Artery De Novo Lesions
Role: collaborator
Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)
Role: collaborator
Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea
Role: lead
Evaluation of the Effectiveness of Managing Chemotherapy Side Effects Using ePRO and a Standardized Telenursing Program for Cancer Patients
Role: lead
Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment
Role: lead
Prospective CT Assessment After DCB
Role: collaborator
Registry of Comprehensive Imaging and Physiological Evaluation of Deferred Lesions Based on FFR
Role: collaborator
Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis
Role: collaborator
Treatment Shortening of MDR-TB Using Existing and New Drugs
Role: collaborator
Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines
Role: collaborator
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
Role: collaborator
Identification of Risk Factors for Cardiovascular Disease and Cancer in Korean Population: A Prospective Cohort Study
Role: lead
BPaL(M) Regimen for the Treatment of MDR/RR-TB
Role: collaborator
Diagnostic Accuracy of Quantitative Flow Ratio
Role: collaborator
Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS
Role: collaborator